FRANKFURT, April 30 (Reuters) - Bayer brushed off concern that its stroke prevention pill Xarelto may be losing market share to rival Bristol-Myers Squibb's Eliquis in the United States.
The German drugmaker told analysts during a conference call on Thursday that Eliquis was taking business from warfarin and other drugs, but not from Xarelto.
18:58 Demi Lovato attacked on Twitter for saying she is 1% African: ‘Some of y’all are mean’20
13:09 JCPenney shuttering up to 140 stores as sales weaken, more sluggish growth seen ahead18
17:21 Stocks mixed after Treasury Secretary points to significant tax reform; industrials lag24
18:41 U.S. home sales hit 10-year high, prices soar19